CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • NEO Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit

Neogenomics (NEO)

Company Profile
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services division serves pharmaceutical clients in clinical trials and drug development. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
Neogenomics logo

Company profile

Ticker
NEO
Exchange
NASDAQ
Website
www.neogenomics.com
CEO
Douglas M. Van Oort
Employees
Incorporated
Nevada
Location
Florida
Fiscal year end
Dec 31
Sector
Professional, Scientific, and Technical Services > Testing Laboratories
Industry (SIC)
Services - Testing Laboratories
Digipath • 20/20 GeneSystems ...
Former names
AMERICAN COMMUNICATIONS ENTERPRISES INC
SEC CIK
0001077183
Corporate docs
Articles of Incorporation & Bylaws
Underwriting Agreements
Plans of Reorganization
Indentures
Material Contracts & Credit Agreements
Subsidiaries Lists
Subsidiaries
Clarient Diagnostic Services, Inc. • Clarient, Inc. • Cynogen, Inc. • Genesis Acquisition Holdings Corp. • Genoptix, Inc. • Inivata Limited, UK Limited Company • Inivata, Inc., Delaware Corporation • Minuet Diagnostics, Inc. • NeoGenomics Bioinformatics, Inc. • NeoGenomics Europe, SA ...
IRS number
742897368

NEO stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$15.40
Low target
$12.00
High target
$18.00
Needham
Upgraded
Buy
$15.00
1 Feb 23
Piper Sandler
Maintains
Overweight
$18.00
14 Nov 22
Raymond James
Maintains
Outperform
$12.00
11 Nov 22
Morgan Stanley
Maintains
Equal-Weight
$17.00
9 Nov 22
SVB Leerink
Maintains
Outperform
$15.00
9 Nov 22
Latest filings (excl ownership)
View all
8-K
Departure of Directors or Certain Officers
23 Jan 23
8-K
NeoGenomics Announces Chief Financial Officer Transition
5 Dec 22
S-8
Registration of securities for employees
5 Dec 22
8-K
Departure of Directors or Certain Officers
18 Nov 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
NeoGenomics Reports Third Quarter 2022 Results
8 Nov 22
8-K
Departure of Directors or Certain Officers
7 Nov 22
8-K
Departure of Directors or Certain Officers
20 Oct 22
S-8
Registration of securities for employees
12 Aug 22
8-K
Departure of Directors or Certain Officers
12 Aug 22
Transcripts
View all
NEO
Earnings call transcript
2022 Q2
9 Aug 22
NEO
Earnings call transcript
2022 Q1
27 Apr 22
NEO
Earnings call transcript
2021 Q4
23 Feb 22
NEO
Earnings call transcript
2021 Q3
4 Nov 21
NEO
Earnings call transcript
2021 Q2
6 Aug 21
NEO
Earnings call transcript
2021 Q1
6 May 21
NEO
Earnings call transcript
2020 Q4
24 Feb 21
NEO
Earnings call transcript
2020 Q3
27 Oct 20
NEO
Earnings call transcript
2020 Q2
28 Jul 20
NEO
Earnings call transcript
2020 Q1
28 Apr 20
Latest ownership filings
View all
5
Vishal Sikri
1 Feb 23
SC 13G/A
BlackRock Inc.
23 Jan 23
4
Cynthia J Dieter
4 Jan 23
4
Melody Harris
4 Jan 23
3
Melody Harris
15 Dec 22
4
Jeffrey Scott Sherman
7 Dec 22
3
Jeffrey Scott Sherman
7 Dec 22
4
Warren Stone
5 Dec 22
3
Warren Stone
1 Dec 22
4
David Brian Perez
7 Nov 22

Financial summary

Financial statements Chart NEO financial data
Quarter (USD) Sep 22 Jun 22 Mar 22 Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 266.13 mm 266.13 mm 266.13 mm 266.13 mm 266.13 mm 266.13 mm
Cash burn (monthly) 5.84 mm 6.47 mm 13.21 mm 14.84 mm 5.42 mm 6.84 mm
Cash used (since last report) 24.44 mm 27.08 mm 55.31 mm 62.12 mm 22.71 mm 28.64 mm
Cash remaining 241.68 mm 239.05 mm 210.82 mm 204.01 mm 243.41 mm 237.48 mm
Runway (months of cash) 41.4 37.0 16.0 13.8 44.9 34.7

Beta Read what these cash burn values mean

Financial data from Neogenomics earnings reports.

Institutional ownership, Q3 2022

NEO institutional ownership history Ownership history
83.9% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 238 238 –
Opened positions 36 30 +20.0%
Closed positions 36 69 -47.8%
Increased positions 72 91 -20.9%
Reduced positions 84 71 +18.3%
13F shares Current Prev Q Change
Total value 912.07 mm 948.69 mm -3.9%
Total shares 105.95 mm 116.24 mm -8.9%
Total puts 120.70 k 151.40 k -20.3%
Total calls 591.00 k 452.50 k +30.6%
Total put/call ratio 0.2 0.3 -39.0%
Largest owners Shares Value Change
BLK Blackrock 21.11 mm $181.75 mm +0.4%
Vanguard 13.17 mm $113.43 mm -1.1%
Brown Advisory 6.18 mm $53.22 mm +7.2%
JHG Janus Henderson 5.96 mm $51.33 mm +470.1%
Wellington Management 3.21 mm $27.63 mm -50.8%
First Light Asset Management 2.72 mm $23.42 mm +0.2%
GS Goldman Sachs 2.65 mm $22.82 mm -22.4%
T. Rowe Price Investment Management 2.57 mm $22.12 mm NEW
Geode Capital Management 2.35 mm $20.23 mm +4.5%
Emerald Advisers 2.14 mm $18.42 mm +76.3%
Largest transactions Shares Bought/sold Change
JHG Janus Henderson 5.96 mm +4.92 mm +470.1%
STT State Street 0.00 -4.10 mm EXIT
Assenagon Asset Management 0.00 -3.61 mm EXIT
Wellington Management 3.21 mm -3.31 mm -50.8%
T. Rowe Price Investment Management 2.57 mm +2.57 mm NEW
Point72 Asset Management 0.00 -2.08 mm EXIT
BCS Barclays 41.89 k -1.60 mm -97.4%
Balyasny Asset Management 25.31 k -1.50 mm -98.3%
Millennium Management 674.64 k -1.49 mm -68.8%
Fred Alger Management 1.63 mm +1.06 mm +184.8%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

NEO insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jan 23 Melody Harris Common Stock Grant Acquire A No No 0 108,225 0.00 108,225
1 Jan 23 Melody Harris Stock Option Common Stock Grant Acquire A No No 9.24 201,613 1.86 mm 201,613
31 Dec 22 Cynthia J Dieter Common Stock Payment of exercise Dispose F No No 0 959 0.00 30,762
31 Dec 22 Vishal Sikri Common Stock Acquire L No No 7.04 225 1.58 k 148,680
5 Dec 22 Jeffrey Scott Sherman Common Stock Grant Acquire A No No 0 89,206 0.00 133,809
5 Dec 22 Jeffrey Scott Sherman Common Stock Grant Acquire A No No 0 44,603 0.00 44,603
5 Dec 22 Jeffrey Scott Sherman Stock Option Common Stock Grant Acquire A No No 11.62 249,169 2.90 mm 249,169
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
1 Feb 23
Analyst Expectations for NeoGenomics's Future
1 Feb 23
Needham Upgrades NeoGenomics to Buy, Announces $15 Price Target
1 Feb 23
Needham analyst Mike Matson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and announces $15 price target.
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
19 Jan 23
NeoGenomics Wins Department Of Veterans Affairs Contract 'Specialized Reference Lab Testing'
9 Jan 23

Press releases

From Benzinga Pro
INVESTOR REMINDER: NEOGENOMICS, INC. (NASDAQ:NEO). Berger Montague Advises Investors to Inquire About a Securities Fraud Action by February 6, 2023
4 Feb 23
PHILADELPHIA, PA / ACCESSWIRE / February 4, 2023 / Berger Montague advises investors that a securities fraud class action lawsuit has been filed against NeoGenomics Inc. ("NeoGenomics") (NASDAQ:NEO) on behalf
NEOGENOMICS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In NeoGenomics To Contact Him Directly To Discuss Their Options
4 Feb 23
NEW YORK, Feb. 4, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against NeoGenomics, Inc. ("NeoGenomics" or the "Company")
NEOGENOMICS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against NeoGenomics, Inc. - NEO
3 Feb 23
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 6, 2023 to file lead plaintiff applications in a
NEOGENOMICS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against NeoGenomics, Inc. and Encourages Investors to Contact the Firm
3 Feb 23
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against F45 Training, Silvergate, NeoGenomics, and Iris and Encourages Investors to Contact the Firm
3 Feb 23
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn